CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference is made to the annual report of China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended 31 December 2020 (the "**2020 Annual Report**") dated 23 March 2021 (the "**Date of the 2020 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2020 Annual Report.

In addition to the information disclosed in the 2020 Annual Report, the Company would like to provide the following further information about the share options granted under the share option scheme adopted by the Company on 29 May 2014 (the "**Share Option Scheme**").

SHARE OPTIONS

As disclosed in the 2020 Annual Report, share options to subscribe for up to 9,660,000 Shares were granted to Mr. He Xun ("**Mr. He**"), an executive Director, on 2 September 2020 at an exercise price of HK$2.00 per Share and share options to subscribe for up to 5,000,000 Shares were granted to a consultant of the Company on 26 November 2020 at an exercise price of HK$2.00 to HK$2.20 per Share. The closing price of the Shares immediately before the date on which share options were granted to Mr. He was HK$1.55 per Share. The closing price of the Shares immediately before the date on which share options were granted to the consultant was HK$1.34 per Share.

On 26 May 2020, the 10% general limit imposed under the rules of the Share Option Scheme on the total number of Shares which may be issued upon the exercise of all options to be granted under the Share Option Scheme was refreshed (the "**Refreshment**"), and share options to subscribe for up to a maximum of 96,980,615 Shares, representing

10% of the then issued Shares, may be granted under the Share Option Scheme as at the date of the Refreshment. Since the date of the Refreshment and up to and including the Date of the 2020 Annual Report, share options to subscribe for up to a total of 14,660,000 Shares were granted as disclosed in the 2020 Annual Report. Hence, as at the date of the 2020 Annual Report, share options to subscribe for up to 82,320,615 Shares may be further granted under the Share Option Scheme. Further, as at the Date of the 2020 Annual Report, share options to subscribe for 50,340,000 Shares were outstanding. Therefore, as at the date of the 2020 Annual Report, a total of 132,660,615 Shares, representing 13.74% of the then issued Shares, were available for issue under the Share Option Scheme.

As disclosed in the 2020 Annual Report, share options were granted to consultants of the Company on 12 January 2018, 20 August 2019 and 26 November 2020 respectively. The grantees of the share options granted on 12 January 2018 were Mr. Bi Wenhan and Mr. Wu Ting Yuk Anthony ("**Mr. Wu**") and the grantee of the share options granted on 20 August 2019 was Mr. Wu as disclosed in the circular of the Company dated 22 April 2020 in relation to, among other things, the Refreshment. For the share options granted on 26 November 2020, the grantee was Dr. Zhai Pu.

GENERAL

Save as supplemented above, the content of the 2020 Annual Report remains correct and unchanged.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 20 September 2021

As at the date of this announcement, the board of Directors comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.